Abstract
This case report documents a middle-aged female patient who remained a SARS-CoV-2 carrier for 32 days, repeatedly testing negative via standard RT-PCR throat swabs despite clear clinical symptoms and radiological evidence of infection. While 17 separate nucleic acid tests were performed over the course of a month, only deep sputum samples eventually yielded positive results. Next-Generation Sequencing (NGS) was employed to confirm the presence of viral genetic material in samples previously labeled negative by RT-PCR, highlighting the critical importance of sample site and detection sensitivity in identifying long-term, low-load viral carriers.
Introduction
Since the outbreak of SARS-CoV-2, RT-PCR has served as the primary diagnostic tool. However, clinicians have frequently encountered patients with classic COVID-19 symptoms and "ground-glass opacities" on CT scans who consistently return negative RT-PCR results from upper respiratory swabs. These "occult" (hidden) carriers pose a significant public health risk, as they can unknowingly spread the virus. This study investigates a specific case to understand the limitations of standard testing and the role of advanced sequencing in bridging diagnostic gaps.
Methods
The patient, a hotel worker with close contact with confirmed COVID-19 cases, was monitored over a month-long isolation period starting February 2. Diagnostic methods included:
- Standard RT-PCR: Targeting the N (nucleocapsid), E (envelope), and R (RdRp) genes.
- Chest Imaging: Longitudinal monitoring via CT scans and radiographs to track lung lesions.
- Next-Generation Sequencing (NGS): Deep sequencing was performed on three specific samples—two throat swabs that were negative by RT-PCR and one positive sputum sample—to detect viral reads that standard PCR might have missed.
- Enhanced Sampling: To improve viral yield, 3% sodium chloride atomization was used to induce the collection of "deep" sputum samples from the lower respiratory tract.
Results
Clinical and Radiological Findings
Upon admission, the patient had been coughing for more than 20 days. Despite initial negative nucleic acid tests on February 7, 8, 11, and 13, a CT scan conducted on February 15 revealed patchy ground-glass opacities in her lungs (Figure 1). This radiological evidence led clinicians to highly suspect SARS-CoV-2 infection despite the lack of molecular confirmation at the time.
Molecular Detection and NGS Success
Out of 17 nucleic acid tests performed, throat swabs remained stubbornly negative or inconclusive. It was not until February 24—the ninth sputum test—that a positive RT-PCR result was obtained.
To investigate the discrepancy, NGS was performed on the "negative" throat swabs from February 22 and 23. As shown in Table 2, NGS successfully identified thousands of SARS-CoV-2 reads in these samples. Specifically, the February 22 throat swab contained 4,035 viral reads, and the February 23 swab contained 1,938 reads, proving that the virus was present even when RT-PCR failed to amplify it.
Following a treatment regimen of Arbidol, chloroquine phosphate, and lopinavir/ritonavir, the patient’s lung lesions were absorbed, and she was discharged on March 12 after meeting negative testing requirements.
Discussion and Conclusion
This case highlights two critical diagnostic challenges: sample site and detection sensitivity. The virus appears to retreat to the lower respiratory tract in later stages of infection, making upper respiratory swabs (throat/nasopharyngeal) unreliable. Furthermore, standard RT-PCR has a sensitivity threshold that may miss low-load carriers.
For future clinical practice, a negative RT-PCR result should not be used in isolation to rule out COVID-19 if clinical symptoms or imaging suggest otherwise. Combining induced sputum collection with high-sensitivity methods like NGS or capture sequencing is essential for identifying and managing long-term viral carriers.
Summary updated